Development
Sarepta Therapeutics, Inc.
SRPT
$16.75
-$0.35-2.05%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 45.66M | -40.94M | -23.94M | -516.76M | -109.24M |
| Total Depreciation and Amortization | 11.37M | 10.93M | 10.79M | 11.31M | 10.55M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 38.61M | 70.02M | -62.06M | 425.11M | 57.69M |
| Change in Net Operating Assets | -150.29M | -154.71M | -47.03M | -129.06M | -51.39M |
| Cash from Operations | -54.66M | -114.71M | -122.23M | -209.40M | -92.39M |
| Capital Expenditure | -19.04M | -29.67M | -17.91M | -9.49M | -7.96M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -45.32M | -180.90M | 114.54M | 21.98M | 17.76M |
| Cash from Investing | -64.36M | -210.57M | 96.63M | 12.49M | 9.80M |
| Total Debt Issued | -- | -- | -- | -- | 0.00 |
| Total Debt Repaid | -- | -- | -- | -- | 0.00 |
| Issuance of Common Stock | 1.94M | 15.41M | 5.86M | 28.04M | 11.30M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | 0.00 | 0.00 | 73.76M | -554.00K |
| Cash from Financing | 1.94M | 15.41M | 5.86M | 101.80M | 10.75M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -117.07M | -309.87M | -19.74M | -95.11M | -71.85M |